Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 215.6 SEK 3.65%
Market Cap: 29.2B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Long-Term Debt
kr1.9B
CAGR 3-Years
230%
CAGR 5-Years
97%
CAGR 10-Years
67%
Biogaia AB
STO:BIOG B
Long-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Long-Term Debt
kr8.5m
CAGR 3-Years
17%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Long-Term Debt
kr68.2m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Long-Term Debt
kr11.7B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
31%
BioArctic AB
STO:BIOA B
Long-Term Debt
kr2.2m
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
29.2B SEK
Industry
Biotechnology

Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.

VITR Intrinsic Value
136.75 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Long-Term Debt?
Long-Term Debt
1.9B SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Long-Term Debt amounts to 1.9B SEK.

What is Vitrolife AB's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
67%

Over the last year, the Long-Term Debt growth was -6%. The average annual Long-Term Debt growth rates for Vitrolife AB have been 230% over the past three years , 97% over the past five years , and 67% over the past ten years .

Back to Top